Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan

Next Previous
X
Search
Trial Profile

A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium (68Ga) gozetotide (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Antineoplastics
  • Indications Carcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 19 Sep 2024 Planned End Date changed from 30 Nov 2028 to 1 Apr 2026.
    • 02 Aug 2024 Planned End Date changed from 30 Apr 2026 to 30 Nov 2028.
    • 01 May 2024 Planned number of patients changed from 28 to 80.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top